2026, 3-4, Anno, Autore, Cancanelli, Confronti Indiretti di Efficacia, Damuzzo, Del Bono, Gasperoni, Gori, Impact factor, Inno, Ossato, Pubblicazioni, Sava, Tessari, Topic, Vecchia
Efficacy and safety of first-line osimertinib monotherapy versus osimertinib plus platinum-based chemotherapy or amivantamab plus lazertinib in metastatic EGFR-mutated NSCLC: an indirect comparison
2024, 3-4, Anno, Autore, Baldo, Cafaro, Cappelletto, Carrucciu, Chiumente, Coppola, Crinò, De Francesco, Delmont, Enrico, Foca, Gasbarro, Gradellini, Impact factor, Ladisa, Lerose, Maiolino, Masini, Nanni, Nardulli, Orzetti, Pasqualini, Provasi, Pubblicazioni, Studi real world, Topic, Vecchia, Veraldi
A real-world retrospective, observational study of first-line pembrolizumab plus chemotherapy for metastatic non-squamous non-small cell lung cancer with PD-L1 tumor proportion score < 50% (PEMBROREAL)
2024, 3-4, Analisi statistiche e metanalisi, Anno, Autore, Impact factor, Mamone, Messori, Pubblicazioni, Rivano, Romeo, Topic, Trippoli, Vaiani
Pulsed-field ablation for paroxysmal atrial fibrillation: An indirect comparison of effectiveness among three proprietary devices conducted in the absence of randomized trials
2024, 3-4, Anno, Autore, Boccardi, Carollo, Conti, Crisafulli, Farmacia clinica, Gnerre, Impact factor, Italian Scientific Consortium on medication review, deprescribing, Marengoni, Miozzo, Omodeo Salè, Onder, Pieraccini, Pubblicazioni, Trifirò, Zamboni